Edition:
United States

Aralez Pharmaceuticals Inc (ARZ.TO)

ARZ.TO on Toronto Stock Exchange

2.23CAD
28 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.23
Open
$2.24
Day's High
$2.24
Day's Low
$2.15
Volume
10,354
Avg. Vol
34,144
52-wk High
$8.75
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Aralez Pharma says co and U.S. Government entered into modification of contract
Tuesday, 11 Apr 2017 04:30pm EDT 

Aralez Pharmaceuticals Inc : Aralez Pharma - on April 6, aralez us and u.s. government entered into modification of contract under which government exercised first renewal option under deal .Aralez Pharmaceuticals Inc - U.S. Government extended term of agreement by one year to April 28, 2018 with modified pricing for duration thereof.  Full Article

Aralez reports reduction in U.S. sales force
Wednesday, 5 Apr 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez announces reduction in U.S. Sales force and cost savings program . Aralez Pharmaceuticals Inc - 32 pct reduction in U.S. sales force . Aralez Pharmaceuticals Inc - reduction in sales force is expected to reduce current annual run rate of operating expenses by approximately $7.5 million . Aralez Pharmaceuticals Inc - sales force restructuring is expected to yield savings for 2017 and beyond . Aralez Pharmaceuticals Inc - strategic realignment of resources with an emphasis on zontivity launch . Aralez Pharmaceuticals says as a result of sales force reduction, anticipates it will incur cash severance costs of approximately $0.6 million in q2 of 2017 . Aralez Pharmaceuticals Inc - company intends to communicate details of the plan in its q1 2017 earnings release to be issued in early may 2017 . Aralez Pharma- plan includes realignment of certain financial resources to support phased launch of zontivity that is expected to begin in mid-april . Aralez Pharmaceuticals Inc says is in process of finalizing its overall cost savings plan . Aralez Pharmaceuticals Inc - cost savings plan includes significant decrease in marketing spend on yosprala .Aralez Pharma-has begun other initiatives expected to reduce spending across business, some of which were already assumed in previously issued financial guidance.  Full Article

Aralez CEO purchases 500,000 shares of company common stock on open market
Monday, 20 Mar 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez Pharmaceuticals- Adrian Adams, CEO, acquired additional 500,000 shares of company's common stock on March 15, 2017 in open-market purchases . Aralez Pharmaceuticals - shares were purchased at an average price of $2.46 per share, for an aggregate purchase price of approximately $1.2 million .Adams now owns about 3.6 million shares of company's common stock.  Full Article

Aralez Pharmaceuticals reports Q4 loss per share $0.48
Monday, 13 Mar 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez reports fourth quarter and full-year 2016 financial results . Qtrly net revenues increased to $20 million versus $6 million in comparable period of 2015 . Sees 2017 net revenues to be in a range of $80 million to $100 million . Aralez Pharmaceuticals Inc qtrly loss per share $0.48 .Sees 2017 adjusted EBITDA to be in a range of a loss of $25 million to a loss of $10 million.  Full Article

Aralez provides update on PBM formulary status for Yosprala
Monday, 9 Jan 2017 06:00am EST 

Aralez Pharmaceuticals Inc : Aralez provides update on PBM formulary status for Yosprala . Entered into a rebate agreement with Express Scripts Inc., which secures formulary status for Yosprala .Rebate agreement with Express Scripts became effective January 1, 2017.  Full Article

Aralez Q2 GAAP loss per share $0.27
Tuesday, 9 Aug 2016 08:00am EDT 

Aralez Pharmaceuticals Inc : Aralez reports second quarter 2016 financial results . Q2 revenue $12.6 million versus $5.2 million . Q2 GAAP loss per share $0.27 .Q2 earnings per share view $-0.22, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

Aralez posts Q1 loss of $0.73/share
Tuesday, 10 May 2016 07:29am EDT 

Aralez Pharmaceuticals Inc : Aralez reports first quarter 2016 financial results . Qtrly GAAP loss per share $0.73 .Total net revenues for three months ended March 31, 2016 were about $8.1 million compared to $4.4 million.  Full Article

Aralez Pharmaceuticals receives Health Canada approval For BLEXTEN
Monday, 25 Apr 2016 07:00am EDT 

Aralez Pharmaceuticals:Says Health Canada approval of BLEXTEN for treatment of symptoms of seasonal allergic rhinitis and chronic spontaneous urticaria.BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc, also a subsidiary of Company.  Full Article

More From Around the Web

No consensus analysis data available.